CERO THERAPEUTICS HOLDINGS, INC. (CERO): Nasdaq/NYSE listing notice — CERo Therapeutics receives Nasdaq delisting notice for equity shortfall, appeals

CERO THERAPEUTICS HOLDINGS, INC.

Nasdaq staff determined company fails minimum $2.5M stockholders' equity requirement for continued listing.
Trading suspension and delisting scheduled for September 8, 2025, unless hearing stays action.
Company requested hearing on September 3, 2025, to appeal determination and present compliance plan.
Plan may include public or private financing to increase equity; no assurance of success.
Company subject to mandatory hearings panel monitor until May 7, 2026, after prior non-compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b), 5815(d)(4)(B)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b), 5815(d)(4)(B)

Exact text from the filing

August 28, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “ Company ”), received a letter from the staff at the Nasdaq Listing Qualifications department notifying the Company that such staff had determined that the Company does not comply with the minimum stockholders’ equity requirement of $2,500,000 (the “ Stockholders’ Equity Requirement ”) for continued listing on the Nasdaq Capital Market (“ Nasdaq ”) set forth in Nasdaq Rule 5550(b). As previously disclosed, the Company previously had been out of compliance with Nasdaq continued listing requirements until, on May 7

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-084498

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.